Evommune, Inc. EVMN
Set alert
6.73 USD -0.08 -1.17%
At close · Oct 30
6.25 -0.48 -7.08%
After hours · Oct 30, 6:02 PM ET
6.29 Day range 6.84
5.10 52-week range 31.57
- YTD
- -60.69%
- 1 year
- -66.73%
- Open
- 6.65
- Prev close
- 6.81
- Mkt cap
- 244.25M
- Vol
- 586.35K
- Avg vol
- 787.66K
- EPS
- -3.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.29
- High
- 6.84
6M chart
Signals (31)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 19, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 21, 2026 | 1 month ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 22, 2026 | 3 months ago |
| RSI: Oversold | Jul 13, 2026 | 3 months ago |
| RSI: Oversold | Jun 30, 2026 | 4 months ago |
| SMA: Bearish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 29, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
Financials — quick view
EVMN Revenue — quarterly 0
EVMN Net income — quarterly -32.25M
EVMN EPS — quarterly -0.89
News
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8
- Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027
- Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
- Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
- Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22
- RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on EVMN — it syncs with the Stock Master app.